Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. ALZN, AEZS, BCLI, SNGX, KLTO, NLSP, SXTP, ADIL, NCNA, and CPHIShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Alzamend Neuro (ALZN), Aeterna Zentaris (AEZS), Brainstorm Cell Therapeutics (BCLI), Soligenix (SNGX), Klotho Neurosciences (KLTO), NLS Pharmaceutics (NLSP), 60 Degrees Pharmaceuticals (SXTP), Adial Pharmaceuticals (ADIL), NuCana (NCNA), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Alzamend Neuro Aeterna Zentaris Brainstorm Cell Therapeutics Soligenix Klotho Neurosciences NLS Pharmaceutics 60 Degrees Pharmaceuticals Adial Pharmaceuticals NuCana China Pharma Alzamend Neuro (NASDAQ:ALZN) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Do analysts rate ALZN or ADXS? Alzamend Neuro currently has a consensus target price of $20.00, suggesting a potential upside of 2,885.07%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ALZN or ADXS? Alzamend Neuro has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ALZN or ADXS? 49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 30.2% of Alzamend Neuro shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor ALZN or ADXS? In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Alzamend Neuro's score of -1.00 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Alzamend Neuro Negative Ayala Pharmaceuticals Neutral Is ALZN or ADXS more profitable? Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Ayala Pharmaceuticals N/A N/A N/A Does the MarketBeat Community believe in ALZN or ADXS? Alzamend Neuro received 7 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave Alzamend Neuro an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes7100.00% Underperform VotesNo VotesAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes83100.00% Which has better earnings and valuation, ALZN or ADXS? Alzamend Neuro has higher earnings, but lower revenue than Ayala Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/AAyala Pharmaceuticals$3.24M0.42-$48.07M-$7.980.00 SummaryAlzamend Neuro beats Ayala Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E Ratio0.006.9521.9417.82Price / Sales0.42231.00380.9497.68Price / CashN/A65.6738.3134.64Price / Book-0.025.936.453.98Net Income-$48.07M$143.22M$3.22B$247.81M7 Day PerformanceN/A4.28%5.85%3.19%1 Month PerformanceN/A-13.11%-9.58%-7.70%1 Year PerformanceN/A-8.51%11.85%1.49% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03flatN/AN/A$1.35M$3.24M0.0020Analyst ForecastALZNAlzamend Neuro2.1921 of 5 stars$0.79+2.8%$20.00+2,434.9%-90.1%$5.22MN/A0.004Short Interest ↑Gap DownAEZSAeterna ZentarisN/A$2.85+1.6%N/A-63.7%$5.11M$2.37M-0.1920Analyst ForecastNews CoverageBCLIBrainstorm Cell Therapeutics3.6011 of 5 stars$0.78+1.8%$30.00+3,765.5%-89.0%$5.06MN/A-0.1640Analyst ForecastSNGXSoligenix1.3013 of 5 stars$1.96-9.7%N/A-69.5%$4.92M$840,000.00-0.2620Short Interest ↓High Trading VolumeKLTOKlotho NeurosciencesN/A$0.17+2.4%N/AN/A$4.87MN/A0.00N/APositive NewsGap UpNLSPNLS PharmaceuticsN/A$1.45+7.4%N/A+1,000.2%$4.86MN/A0.006Short Interest ↓Positive NewsGap UpSXTP60 Degrees Pharmaceuticals1.2811 of 5 stars$3.26+10.1%N/A+162.2%$4.80M$607,574.00-0.323Short Interest ↓Gap UpADILAdial Pharmaceuticals2.4852 of 5 stars$0.72+2.1%$8.00+1,003.8%-64.5%$4.77MN/A-0.2220Positive NewsNCNANuCana2.6482 of 5 stars$0.83+10.6%$25.00+2,913.5%-77.2%$4.71MN/A-0.0830Positive NewsCPHIChina PharmaN/A$0.14-0.8%N/A-95.3%$4.61M$4.53M0.00250Analyst ForecastNews Coverage Related Companies and Tools Related Companies Alzamend Neuro Alternatives Aeterna Zentaris Alternatives Brainstorm Cell Therapeutics Alternatives Soligenix Alternatives Klotho Neurosciences Alternatives NLS Pharmaceutics Alternatives 60 Degrees Pharmaceuticals Alternatives Adial Pharmaceuticals Alternatives NuCana Alternatives China Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXS Stock Free ADXS Stock Alerts